Answers are grounded in this paper and cite their sources.
Shows rosiglitazone reduces fibrinogen and glycated hemoglobin across diabetic and prediabetic metabolic syndrome patients, indicating divergent effects on inflammation and uric acid.
The aim of this study was to examine the effects of hypoglycaemic drug-agonists of PPAR-gama receptors-rosiglitazone (Avandia,4 mg - Glaxo Smith Kline) on values of wide-spread risk - markers-fibrinogen, C-reactive protein and uric acid and glicolysated haemoglobin HbA1C as parameter of metabolic control .We included fourty patients with criteria for metabolic syndrome and evaluated results into groups of diabetic and prediabetic patients according to criteria of IDF (International Diabetic Federation)These risk markers and glicolysated haemoglobin HbA1C were observed at the start of therapy, then after four, eight and twelve weeks and results were compared and statistically calculated. Three months initial therapy with rosiglitazone significantly reduced values of HbA1C, fibrinogen and CRP but not uric acid in prediabetic patients.Rosiglitazone initial three months therapy significantly reduced HbA1C, fibrinogen and uric acid, but not CRP in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Macić-Džanković et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: